Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review
- Author(s)
- Dato, PE; De La Cerda, J; Armstrong, AJ; Azad, AA; Conduit, C; Haas, GP; Kernen, K; Klaassen, ZW; Patel, R; Saad, F; Shore, ND; Freedland, SJ; Karsh, LI;
- Details
- Publication Year 2026-02,Volume 22,Issue #5,Page 605-616
- Journal Title
- Future Oncology
- Publication Type
- Review
- Abstract
- GOAL: To present data from published clinical trials of treatment of patients with prostate cancer with enzalutamide described in plain language and in a dashboard format available at: https://clinical-trials.dimensions.ai/enzalutamide-clinical-review/. RATIONALE: Treatments that are clinically active in advanced prostate cancer may benefit patients as they are treated earlier in the disease. OBJECTIVE: To show how overall survival improves as patients are treated with enzalutamide earlier in the disease.
- Publisher
- Taylor & Francis
- Keywords
- Humans; Male; Nitriles; *Phenylthiohydantoin/analogs & derivatives/therapeutic use/administration &; dosage; Benzamides; *Prostatic Neoplasms, Castration-Resistant/drug therapy/mortality/pathology; *Prostatic Neoplasms/drug therapy/mortality/pathology; *Antineoplastic Agents/therapeutic use; Treatment Outcome; Clinical Trials as Topic; Neoplasm Staging; Plain language review; advanced prostate cancer; enzalutamide; metastasis-free survival; overall survival; patient-reported outcomes; prostate cancer; prostate neoplasms
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1080/14796694.2025.2475730
- Open Access at Publisher's Site
https://doi.org/10.1080/14796694.2025.2475730- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-07-22 06:23:46
Last Modified: 2026-02-19 05:52:46